Milestone Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
25.4%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$0.83next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Corporate Update | 11 Nov 2026 |
Monitoring Framework
Key Performance Indicators
CARDAMYST (etripamil) Net Product Revenue Quarterly200KTarget: Establish commercial traction following late January 2026 retail pharmacy launch
Total Captured Prescriptions for CARDAMYST Quarterly600.0Target: Expand prescriber base and patient adoption
Unique Prescribers Initiating Patients on CARDAMYST Quarterly400.0Target: Increase breadth of unique prescribers writing scripts
Cash, Cash Equivalents, and Short-Term Investments Quarterly184.2MTarget: Maintain sufficient runway to fund operations and clinical trials into H2 2027
Watch Items
- Payer Coverage and Formulary WinsTrigger: Securing coverage with major PBMs representing over 80% of commercially covered livesAction: Monitor pull-through of Express Scripts national formulary coverage (secured March 2026) and upcoming UnitedHealth coverage (effective July 2026)
- ReVeRa-301 Phase 3 Trial EnrollmentTrigger: First patient enrollment in the Phase 3 registrational program for AFib-RVRAction: Track onboarding of clinical sites and initiation of patient enrollment scheduled for H2 2026
- International Regulatory ApprovalsTrigger: Acceptance and review of New Drug Applications in Greater China and EuropeAction: Monitor progress of the EMA Marketing Authorization Application (MAA) and the NMPA NDA in China (accepted Jan 17, 2025)
Research as of 20 Jun 2026